L. Kabasakal Et Al. , "Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry," MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , vol.26, no.2, pp.62-68, 2017
Kabasakal, L. Et Al. 2017. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , vol.26, no.2 , 62-68.
Kabasakal, L., Toklu, T., Yeyin, N., Demirci, E., Abuqbeitah, M., Ocak, M., ... Aygun, A.(2017). Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , vol.26, no.2, 62-68.
Kabasakal, Levent Et Al. "Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry," MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , vol.26, no.2, 62-68, 2017
Kabasakal, Levent Et Al. "Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry." MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , vol.26, no.2, pp.62-68, 2017
Kabasakal, L. Et Al. (2017) . "Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry." MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , vol.26, no.2, pp.62-68.
@article{article, author={Levent Kabasakal Et Al. }, title={Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry}, journal={MOLECULAR IMAGING AND RADIONUCLIDE THERAPY}, year=2017, pages={62-68} }